PIH9 COSTS TO THE NATIONAL HEALTH INSURACE SCHEME OF THE FREE MATERNAL HEALTH SERVICE CHALLENGES AND IMPLICATIONS FOR SUSTAINABILITY IN GHANA  by Odame, E.
OBJECTIVES: Evaluate comparative effectiveness and economic impacts of banked
donor milk for premature infants to support evidence-based decision-making for
implementing a public milk bank managed by a blood bank in the province of
Québec.METHODS:A systematic review of the literaturewas performed to identify
clinical benefits of banked donor milk compared to formulas for reducing compli-
cations in preterm or very low birthweight (VLBW) infants. Epidemiology and costs
of these complications were obtained from provincial databases (Régie de
l’Assurance Maladie du Québec; Ministère de la Santé et des Services Sociaux) to
estimate the economic impact of using banked donor milk in this vulnerable pop-
ulation. Milk bank budget was estimated in the context of the Québec blood bank.
RESULTS: Evidence available indicates that the major benefit associated with the
use of banked donor milk compared to formula in premature or VLBW infants is a
reduction by 70% of the rate of necrotizing enterocolitis (NEC). Based on historical
data, the incidence rate of NEC in the province of Québec, Canada, was of 70 cases
during a one year-period between 2008 and 2009which resulted in total direct costs
of 2010US$5,426,128 for the Québec healthcare system. It is estimated that the use
of banked donor milk in neonatalogy would reduce the number of NEC cases by 49
and the number of fatalities by 12 annually, resulting in potential savings. It is
proposed that implementing a public milk bank in a blood bank setting would
result in economic efficiencies CONCLUSIONS: Findings of the present study un-
derlines the clinical benefits of banked donor milk compared to formulas in reduc-
ing the incidence of NEC in premature infants. Implementing a public milk bank in
a blood bank setting could be clinically and economically beneficial.
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OBJECTIVES: Atypical femoral diaphyseal fracture and long-term alendronate use
may be linked. The protective effect and the risk of atypical femoral fracture of alen-
dronateandotheranti-osteoporosisdrugs inolderTaiwanesewomenwereevaluated.
METHODS: A population-based retrospective cohort was obtained from the 2000 to
2009 Taiwan National Health Insurance (NHI) data. Subjects hospitalized with verte-
bral or hip fracture to 2007 were selected using 2000 as a run-in year to identify inci-
dent osteoporotic fractures. All patients receiving alendronate, raloxifene, calcitonin
salmon, or teriparatide after index fracture diagnosis formed the treated cohort. An
untreated cohort was obtained accordingly. Patients were followed until endpoint
(hospitalization for hip fracture or atypical femoral diaphyseal fracture) or end of
study period. Cox proportional hazards models were used to assess the association
between alendronate and other anti-osteoporosis drugs and fracture risks. RESULTS:
Among the 11,278 patients (mean age, 77 years), 2,425 (21.5%) received alendronate
(mean follow-up, 1228797days), 2,694 (23.9%) received other anti-osteoporosis drugs
(mean follow-up, 1069639days), and6,159 (54.6%) remaineduntreated (mean follow-
up, 1357835 days). Head-to-head comparisons revealed alendronate’s superiority
(HR 0.77, 95% CI 0.62–0.95) over other anti-osteoporosis drugs in hip fracture preven-
tion. The risk of subsequent hip fracture was significantly reduced (adjusted HR 0.27,
95%CI 0.15–0.78) in long-termalendronateusers. Risk of atypical femoral fracturewas
similar for alendronate versus other anti-osteoporosis drugs (adjustedHR 0.49, 95%CI
0.40–1.47). Short- or long-term alendronate usewas not associatedwith higher risk of
atypical femoral fractures.CONCLUSIONS:Alendronate poses no greater risk of atyp-
ical femoral fracture than other agents, and its benefits in reducing hip fracture risk
significantly outweigh this concern.
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OBJECTIVES: This study evaluated the persistent use of psychotropic polyphar-
macy and characterized how well the cross-sectional operational definitions of
polypharmacy used in published pediatric studies accurately identify patients’
prescribed long-term treatment.METHODS:The prevalence of psychotropic polyp-
harmacy was defined as receiving 14 days, 30 days, 60 days, and 90 days of
overlapping psychotropic prescription fills. Descriptive analysis was used to com-
pare the prevalence findings based on Multistate Medicaid data involving children
and adolescents 6 to 18 years of age. A sensitivity analysiswas conducted to further
explore the extent to which the cross-sectional operational definitions of poly-
pharmacy used in published literature identified patients who were prescribed
psychotropic combinations on a long-term basis. RESULTS: Analysis of Multistate
Medicaid data revealed that 218,696 children and adolescents filled at least one
psychotropic prescription in 2005. Of these patients, 22.52% received psychotropic
combinations for 14 consecutive days. The observed rate of polypharmacy
dropped to 21.07% with 30 days overlap criterion and to 16.44% with 60 days
overlap criterion. 25%-60% of patients with polypharmacy in cross-sectional defi-
nitions were likely receiving two or more psychotropic agents on a short-term
basis.. Furthermore, cross-sectional definitions failed to identify a 40% to 70% of
patients on long-term polypharmacy (60 day overlap). CONCLUSIONS: The long-
term use of psychotropic polypharmacy in Medicaid children and adolescents in
this study appeared modest. The comparison between our observations and pre-
vious studies illustrate the considerable problems that arise when comparing rates
of polypharmacy across studies with inconsistent operational definitions.
PIH7
POTENTIALLY INAPPROPRIATE MEDICATION USE AMONG OLDER ADULTS IN
THE UNITED STATES IN 2007
Zhang YJ1, Liu WW2, Guo JJ1
1University of Cincinnati, Cincinnati, OH, USA, 2Academy of Military Medical Sciences, Beijing,
China
OBJECTIVES: To determine the prevalence of potentially inappropriatemedication
(PIM) use among older adults in theUSA in 2007 and compare the prevalence to that
in 1996, and to identify risk factors for PIMuse.METHODS: Primary data sourcewas
the 2007 Medical Expenditure Panel Survey. This is a nationally representative
survey of the U.S. community-dwelling population. Study subjects were those re-
spondents aged 65 or older. A retrospective cohort studywas conducted. PIMswere
identified according to the Zhan criteria. Prevalence rates of the 33 PIMs utilization
bymedications and respondents’ characteristics were determined. Risk factors for
PIM use were examined using logistic regression after controlling for confounding
factors.RESULTS:The 33 PIMsuse on the Zhan list declined between 1996 and 2007.
In 2007, 13.8% (95% confidence interval [CI], 12.5%–15.2%) of the elderly or 5.4 mil-
lion older adults received at least 1 of the 33 PIMs; and 1.5% (95%CI, 1.1%–2.0%) used
at least 1 of the 11 PIMs that should always be avoided. The most commonly
misused medications were propoxyphene, amitriptyline, antihistamines, diaze-
pam, muscle relaxants, gastrointestinal antispasmodics, and indomethacin. High-
risk older patients for PIM use included women, people in the South, persons re-
ceiving more prescriptions, and those who rated their health status as fair and
poor. Comparing to data in 1996, the prevalence of PIMs decreased from 6.9million
to 5.4 million although the top three PIMs remained propoxyphene, amitriptyline
and promethazine. The older people who took at least 1 of the 11 PIMs declined
from 0.84 million to 0.59 million. CONCLUSIONS: The 33 PIMs use in older Ameri-
cans decreased butwas still prevalent in some subgroups and for some drugs. Drug
utilization review for elderly population is still needed.
Individual’s Health – Cost Studies
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OBJECTIVES: The purpose of this study is to describe health service use and related
costs associated with potentially inappropriate prescriptions (PIP) of benzodiaz-
epines (BZD) in the elderly living in the community in the province of Quebec,
Canada. METHODS: The cohort consisted of a representative sample (n2494) of
Quebec’s community-dwelling elderly (65 years of age) respondents of the ESA
survey (Survey on older adult’s mental health, 2006). The cost analysis was carried
out from a healthcare system perspective and the definition of the PIP of benzodi-
azepines was based on Beers’ criteria (Fick, 2003). Multivariate regression analyses
were carried out to assess the influence of PIP of BZD on healthcare costs in the
elderly. RESULTS: 30% (n744) of participants were using BZD and 45% (n331) of
the users received at least one PIP. Higher healthcare costs (14196$ vs. 9992$; p
0.0001) were observed for participants with the presence of PIP of BZD in compar-
ison with those without PIP. When individual and health care system factors were
controlled, health care costs were still higher for BZD users with PIP without being
statistically significant at a 95% level ( (log($))  0.109; IC95: [-0.040, 0.259]; 	 $ :
1180$). Factors associated with higher healthcare costs were gender and physical
health status. CONCLUSIONS: Using both administrative and survey data, this
study provides new data that will help decision makers better understand the
economic impact associated with the inappropriate prescriptions of BZD. The sig-
nificant association between the PIP of BZD and the healthcare costs observed in
the univariate analysis seems to be mainly explained by the patient’s physical
health status. Nonetheless, with the current economic and clinical context, partic-
ular attention should be given to the inappropriate prescriptions of BZD, affecting
45% of users and 14% of the senior population in Québec.
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OBJECTIVES: Themain objective of this study was therefore to examine the cost of
the freematernal health services to the southern part of Ghana and explore factors
that contribute to these costs. METHODS: Available routine financial claim records
for 2009 were used to compile the cost information for the various maternal services
usingacompilation sheet for the threenational insurance schemeaccredited facilities
and the scheme office in the area. The financial cost of antenatal, postnatal, delivery,
abortion and the overall costs of all the maternal health services were obtained by
facility type for both services and drugs. RESULTS: Among other findings, we found
that average cost for Ridge hospital antenatal GH¢14.28(US$9.85), postnatal
GH¢63.54(US$43.82) andnormal deliveriesGH¢51.03(US$35.19)whereas that forAdab-
raka Polyclinic antenatal GH¢15.12(US$10.43), postnatal GH¢24.03(US$16.58) and nor-
mal deliveries GH¢37.64(US$25.96). The results of the study showed that
GH¢1,358,647.98(US$936,998.61) was spent in 2009 for maternity services for Osu-
Klottey sub-metro and this represented about 7.7%of expenditure of theBritishGrant.
The financial cost of antenatal care was GH¢289,094.96(US$199,375.83), postnatal
care was GH¢159,913.34(US$110,285.06) and spontaneous vaginal delivery was
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GH¢205,452.58 (US $141,691.44). CONCLUSIONS: This study showed that average
costs of maternity services were consistently higher at hospitals. The lower health
facilities were under utilized.
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OBJECTIVES: Cost burden of menorrhagia or heavy menstrual bleeding (HMB) has
not been well documented. This study evaluated the healthcare resource utiliza-
tion, work productivity loss, and costs associatedwith newly diagnosed HMB using
a large employer database. METHODS: An analysis was conducted of health in-
surance claims (1998-2009) from 40 self-insured companies across the US.
Women aged 18-52 years with 2 diagnosis claims of HMB (ICD-9: 626.2, 627.0)
within 6 months as of the date of the first HMB diagnosis (“index date”) and
continuously enrolled for 6 months prior to the index date were matched 1:1
with controls (no-HMB) based on exact matching factors and propensity scores.
Exclusion criteria were diagnosis of cancer, pregnancy/delivery, clinician-iden-
tified uterine conditions, endometrial ablation or hysterectomy, diagnosis of
organic causes of HMB, and dispensing of anticoagulant medications. All-cause
healthcare resource utilization and costs were compared between the HMB and
no-HMB control cohorts using statistical methods accounting formatched study
design. RESULTS: The HMB and no-HMB cohorts (31,308 women in each group)
were well-matched with respect to age, year of index date, region, comorbidi-
ties, and baseline costs. During follow-up, HMB patients had significantly higher
all-cause resource utilization than no-HMB patients (hospitalization: incidence
rate ratio [IRR]2.68, 95% CI:2.59-2.76, p.0001; emergency room: IRR1.36, 95%
CI:1.33-1.40, p.0001; outpatient: IRR1.29, 95% CI:1.28-1.29, p.0001]. Average
annualized (per-patient-per-year) all-cause healthcare and work productivity
loss costs were also significantly higher for HMB patients compared to the no-
HMB group ($6,275 vs. $3,740, cost difference$2,535, p.0001). Costs associated
with HMB claims represented 50% ($1,261) of the all-cause cost difference be-
tween the two cohorts. Themost prevalent initial treatment following diagnosis
of HMB was endometrial ablation (45% of patients). CONCLUSIONS: In this large
matched-cohort study, a diagnosis of HMB was associated with significantly
higher healthcare resource utilization and costs.
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OBJECTIVES: Parenteral nutrition (PN) is critical for neonatal care and for infantswho
are unable to tolerate oral or enteral feeding during this important growth period. PN
for these populations is highly complex and involves a multidisciplinary approach.
This study aims to assess the total cost of compounded PN therapy for neonates,
infants, and children.METHODS: A cost-model was constructed to assess total costs
of PN therapy including prescribing, compounding, and administration. This tool was
piloted in 3 Belgian hospitals, with a total of 763 patients and 7,488 compounded bags
annually. Data were collected via literature review and face-to-face interviews in 12
hospitals in4countries (Belgium,France,Germany,andUK)about resource-utilization
and costs. The variable and fixed costs such as ingredients, consumables, equipment,
staff-time were included. Overall costs of hospital PN-therapy were calculated from
expenditures. Staff-time spent preparing PN was measured to determine personnel
costs; bottom-up costing was used to assign a monetary value using published
list-prices. RESULTS: In these hospitals, 93% of all PN bags were compounded in-
hospital (either in the pharmacy or on the ward), and 7% were industrially manufac-
tured. The daily total cost of one bag of in-hospital compounded PN equaled €51.68
(weighted average by PN days) per neonate across all weight groups. Consumables
accounted for 25% of total costs, ingredients 21%, equipment 4% and wages 50%; 22
minutes of staff-timeper PNwasuniquely attributable to compounding, not including
time required for prescribing and supplementation. Average costs per bag using phar-
macy compounding for children2 yrs was €71.47, and for children 2-18 years €71.03,
of which 45% were attributed to ingredients and 35% to wage-costs, respectfully.
CONCLUSIONS: The data showed that a significant proportion of the total cost of PN
wasdue tostaff-time.ReadypreparedPNcould reducestaff-timespentoncompound-
ing for patient-related activities.
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OBJECTIVES: Despite efforts to decrease the incidence of low birth weight (LBW)
and pre-term infants, rates for these conditions have continued to rise in recent
years. The objective of this study was to determine the recent prevalence of and
burden associated with hospitalizations among LBW and pre-term infants in the
United States (US).METHODS: This study used data from the 2008 Healthcare Cost
and Utilization Project Nationwide Inpatient Sample. Hospital stays were selected
for inclusion if the patient was aged 1 year old. Stays were broken into three
categories: LBW/pre-term stays (any diagnosis with an ICD-9-CM code of 764.xx,
765.xx, and V21.3x), uncomplicated newborn stays (primary diagnosis with an ICD-
9-CM code between V30 and V39.2), and all other infant stays. LBW/pre-term stays
were stratified by infants weighing less than or greater than 2,500 grams. Study
measures were weighted and included demographics, hospital characteristics,
length of stay (LOS), and costs. RESULTS: In 2008 there were 499,473 stays for
LBW/pre-term infants, representing 10% of all infant stays. The average LOS for
LBW/pre-term infants was 11.9 days, versus 2.3 days among infants with an un-
complicated newborn stay, and 4.2 days among all other infant stays. LBW/pre-
term infant stays resulted in costs of more than $9.7 billion, or approximately 45%
of all costs for all infant stays, and nearly 1.7 times the costs of uncomplicated
newborn stays. Patients with a birth weight less than 2,500 grams had costs that
were approximately 3.9 times greater than costs for patients with a birth weight
greater than 2,500 grams (mean [SE] $23,382 [$1,220] versus $5,951 [$350] among
patients with a birth weight less than versus greater than 2,500 grams,
respectively). CONCLUSIONS: While LBW/pre-term infant stays represent a small
percentage of all infant hospitalizations, they accrue almost half of all inpatient
costs among infants.
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OBJECTIVES: To evaluate the cost-effectiveness of the LNG-IUS compared with
other therapies for the treatment of heavymenstrual bleeding (HMB) in the United
States (US). METHODS: A microsimulation model examined the five-year treat-
ment experiences of 1,000 hypothetical womenwithHMB fromaUS payer perspec-
tive. Women could begin treatment with LNG-IUS, four oral agents (generic com-
bined oral contraceptives (COCs), branded COCs, oral progestogens, or tranexamic
acid) or surgery (endometrial ablation or hysterectomy). Womenwho failed a non-
surgical treatment line could switch to another non-surgical or surgical therapy (up
to three non-surgical treatment lines were allowed). Women who failed all non-
surgical treatment lines had the option of surgery as a fourth-line treatment. Treat-
ment success was defined as menstrual blood loss  80 milliliters per menstrual
cycle (data were obtained from recent literature). Women could also experience
adverse events, unintended pregnancy, or discontinue treatment during any treat-
ment line (probabilities of these events varied by treatment). Response to treat-
ment was evaluated every three months. The outcome of interest was cost per
hysterectomy avoided. Robustness of model results was tested in Monte Carlo
probabilistic sensitivity analyses. RESULTS: Initiating HMB treatment with LNG-
IUS dominated all other strategies: it was the least costly ($1,253 per woman) and
resulted in fewer hysterectomies (6 per 1,000 women) compared with the other
strategies (costs ranged from$2,291 for generic COCs to $18,219 for hysterectomies;
number of hysterectomies per 1,000 women ranged from 9 for ablation to 96 for
progestogens). Two years of treatment with LNG-IUS was less costly and more
effective than other treatments, except for ablation, which was more costly but
more effective than LGN-IUS. Sensitivity analyses confirmed these results.
CONCLUSIONS: Initiating treatment after five years with LNG-IUS results in fewer
hysterectomies and is a cost-saving, or highly cost-efficient, treatment for HMB
compared with strategies beginning with oral therapies or surgery.
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OBJECTIVES: Over two thirds of women who need contraception in Uganda lack
access to modern effective methods. This study was conducted to estimate the
potential cost-effectiveness of achieving universal access to modern contracep-
tives in Uganda by implementing a hypothetical New Contraceptive Program (NCP)
from both societal and governmental perspectives. METHODS: A Markov model
was developed to compare the NCP to the status quo or Current Contraceptive
Program (CCP). Themodel followed a hypothetical cohort of 15-year old girls over a
lifetime horizon. Data were obtained from the Uganda National Demographic and
Health Survey and frompublished andunpublished sources. Costs, life expectancy,
disability-adjusted life expectancy, pregnancies, fertility and incremental cost-ef-
fectiveness measured as cost per life-year (LY) gained, cost per disability-adjusted
life-year (DALY) averted, cost per pregnancy averted and cost per unit of fertility
reduction were calculated. Univariate and probabilistic sensitivity analyses were
performed to examine the robustness of results. RESULTS: Mean discounted life
expectancy and disability-adjusted life expectancy (DALE) were higher under the
NCP vs. CCP (28.74 vs. 28.65 years and 27.38 vs. 27.01 respectively). Mean pregnan-
cies and live births perwomanwere lower for theNCP (9.51 vs. 7.90 and 6.92 vs. 5.79
respectively). Mean lifetime societal costs perwomanwere higher for theNCP from
the societal perspective ($1,074 vs. $1,041) and the governmental perspective ($448
vs. $397). The incremental cost-effectiveness ratio comparing the NCP to the CCP
was $88 per DALY averted (societal perspective) and $138 per DALY averted (gov-
ernmental perspective). The results were robust to univariate and probabilistic
sensitivity analysis. CONCLUSIONS: Universal access to modern contraceptives in
Uganda appears to be highly cost-effective. Increasing contraceptive coverage
should be considered among Uganda’s public health priorities.
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